41 results
DEFR14A
OCX
Oncocyte Corporation
22 May 23
Revised proxy
9:00am
and board positions with other public and private companies.
Director Independence
Our Board of Directors has determined that Jennifer Levin Carter … . Carter and Mr. Gutfreund are not standing for reelection. The members of our Audit Committee meet the additional independence standards under Nasdaq
8-K
EX-1.1
0gtr3zmloaqce
19 Apr 22
Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants
4:01pm
8-K
EX-1.1
t3eze
14 Jun 21
Entry into a Material Definitive Agreement
12:00am
8-K
EX-1.1
ud5hnijn
5 Feb 21
Oncocyte Announces Pricing of $35 Million Public Offering of Common Stock
5:15pm
PRER14A
imvpby lfj9
18 May 20
Preliminary revised proxy
6:06am